Vonafexor市場：市場規模、予測、新たな洞察-2032年

Vonafexor（EYP001）は、経口投与可能な非ステロイド性合成胆汁酸FXRアゴニストで、NASH治療薬として開発された低分子化合物です。FXRアゴニストが将来のNASH治療の基幹薬になる可能性があることは、多くのKOLが認めています。ステリックマウスモデルSTAMにおいて、ほとんどのNASH主要パラメータ（線維化、脂肪症、炎症、バルーン形成、トリグリセリド、NAS）に有意なプラスの影響を与え、その有効性を実証しています。本薬は、他のFXRアゴニストとは異なるユニークな化学的特性とPK PDプロファイルを有し、クラス最高の治療指標を提供する可能性があります。

Vonafexor（EYP001）は現在、進行性NASH、すなわち線維化ステージF2またはF3の患者を対象とした第IIa相臨床試験で評価されています。中間安全性解析の結果、良好な忍容性が確認されたため、独立委員会（DSMC）は、予定通り臨床試験を完了させることを提案しました。慢性B型肝炎とNASHを対象に、主要化合物Vonafexorの3つの第II相臨床試験が実施されています。

当レポートでは、主要7ヶ国におけるVonafexor市場について調査し、市場の概要とともに、競合情勢、2032年までの市場規模予測、および国別市場分析などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 非アルコール性脂肪肝炎（NASH）におけるVonafexorの概要

• 製品詳細
• 臨床開発
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 Vonafexor市場評価

• 非アルコール性脂肪肝炎（NASH）におけるボナフェクソールの市場見通し
• 主要7ヶ国分析
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: Vonafexor, Clinical Trial Description, 2023
• Table 2: Vonafexor, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Vonafexor Market Size in the 7MM, in USD million (2019-2032)
• Table 6: Vonafexor Market Size in the US, in USD million (2019-2032)
• Table 7: Vonafexor Market Size in Germany, in USD million (2019-2032)
• Table 8: Vonafexor Market Size in France, in USD million (2019-2032)
• Table 9: Vonafexor Market Size in Italy, in USD million (2019-2032)
• Table 10: Vonafexor Market Size in Spain, in USD million (2019-2032)
• Table 11: Vonafexor Market Size in the UK, in USD million (2019-2032)
• Table 12: Vonafexor Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Vonafexor Market Size in the 7MM, USD million (2019-2032)
• Figure 2: Vonafexor Market Size in the United States, USD million (2019-2032)
• Figure 3: Vonafexor Market Size in Germany, USD million (2019-2032)
• Figure 4: Vonafexor Market Size in France, USD million (2019-2032)
• Figure 5: Vonafexor Market Size in Italy, USD million (2019-2032)
• Figure 6: Vonafexor Market Size in Spain, USD million (2019-2032)
• Figure 7: Vonafexor Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: Vonafexor Market Size in Japan, USD million (2019-2032)

"Vonafexor Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Vonafexor for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Vonafexor for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Vonafexor for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Vonafexor market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Vonafexor (EYP001) is an orally bioavailable synthetic non-steroidal, non-bile acid FXR agonist small molecule also developed in NASH. Most KOL agrees that FXR agonists could become the backbone of future NASH therapies. It has demonstrated its efficacy in a stelic mouse model STAM with a significant positive impact on most NASH key parameters (fibrosis, steatosis, inflammation, ballooning, triglycerides, and NAS). It differentiates from other FXR agonists with a unique chemistry and PK PD profile to possibly provide a best-in-class therapeutic index.

Vonafexor (EYP001) is currently evaluated in a Phase IIa clinical trial in patients with advanced NASH, i.e., a fibrosis Stage F2 or F3. After the interim safety analysis showed good tolerance, the independent DSMC suggested pursuing the trial to completion as planned. The company conducts three Phase II trials with its lead compound Vonafexor in Chronic Hepatitis B and NASH.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Vonafexor description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Vonafexor regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Vonafexor research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Vonafexor.
• The report contains forecasted sales of Vonafexor for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Vonafexor in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Vonafexor Analytical Perspective by DelveInsight

• In-depth Vonafexor Market Assessment

This report provides a detailed market assessment of Vonafexor for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• Vonafexor Clinical Assessment

The report provides the clinical trials information of Vonafexor for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Vonafexor dominance.
• Other emerging products for NASH are expected to give tough market competition to Vonafexor and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Vonafexor in NASH.
• Our in-depth analysis of the forecasted sales data of Vonafexor from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Vonafexor in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of Vonafexor?
• What is the clinical trial status of the study related to Vonafexor in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Vonafexor development?
• What are the key designations that have been granted to Vonafexor for NASH?
• What is the forecasted market scenario of Vonafexor for NASH?
• What are the forecasted sales of Vonafexor in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Vonafexor for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. Vonafexor Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Vonafexor Market Assessment

• 5.1. Market Outlook of Vonafexor in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Vonafexor in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Vonafexor in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of Vonafexor in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of Vonafexor in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of Vonafexor in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of Vonafexor in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of Vonafexor in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of Vonafexor in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options